Cancer patients have increased risk of severe cutaneous adverse reactions, without reliable biomarkers to identify predisposition for associated morbidity and mortality. In hospitalized cancer patients with morbilliform rash, elafin, IL-6, TNF-α were associated with mortality. IL-6, IL-10 were associated with drug-related systemic involvement. These biomarkers may guide future therapeutic research.
https://ift.tt/2PZSZhE
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου